Sartorius (FRA:SRT3) Given a €184.00 Price Target by UBS Group Analysts

Share on StockTwits

Sartorius (FRA:SRT3) has been given a €184.00 ($213.95) price target by analysts at UBS Group in a report issued on Monday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the stock. UBS Group’s target price would indicate a potential upside of 3.90% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Nord/LB set a €125.00 ($145.35) target price on Sartorius and gave the stock a “sell” rating in a report on Monday, July 22nd. Berenberg Bank set a €145.00 ($168.60) price objective on Sartorius and gave the company a “sell” rating in a research note on Thursday, July 25th. Deutsche Bank set a €170.00 ($197.67) price objective on Sartorius and gave the company a “neutral” rating in a research note on Tuesday, October 15th. Hauck & Aufhaeuser set a €135.00 ($156.98) price objective on Sartorius and gave the company a “sell” rating in a research note on Friday, August 23rd. Finally, HSBC set a €160.00 ($186.05) price objective on Sartorius and gave the company a “neutral” rating in a research note on Wednesday, October 16th. Five investment analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. Sartorius has an average rating of “Sell” and an average target price of €147.61 ($171.64).

Shares of SRT3 stock opened at €177.10 ($205.93) on Monday. The stock has a 50 day simple moving average of €170.41 and a two-hundred day simple moving average of €172.81. Sartorius has a fifty-two week low of €71.00 ($82.56) and a fifty-two week high of €124.70 ($145.00).

About Sartorius

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

See Also: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Rapids Price Reaches $0.0001 on Exchanges
Rapids Price Reaches $0.0001 on Exchanges
GAPS  24 Hour Volume Hits $1.65 Million
GAPS 24 Hour Volume Hits $1.65 Million
BOOM  One Day Volume Tops $6,370.00
BOOM One Day Volume Tops $6,370.00
$382.50 Million in Sales Expected for Quaker Chemical Corp  This Quarter
$382.50 Million in Sales Expected for Quaker Chemical Corp This Quarter
$4.11 Billion in Sales Expected for Core-Mark Holding Company, Inc.  This Quarter
$4.11 Billion in Sales Expected for Core-Mark Holding Company, Inc. This Quarter
Saia  Stock Rating Lowered by BidaskClub
Saia Stock Rating Lowered by BidaskClub


 
© 2006-2019 Zolmax.